Doctors are warning that the illegal use of retatrutide—sometimes marketed as “Reta”—poses risks because the medicine is not yet approved by health regulators. Multiple reports describe retatrutide as an appetite-suppressing drug intended for weight loss that is being compared to other widely used medications such as Mounjaro and Ozempic, but emphasize that retatrutide is still in clinical trials. Because it is not authorised for general prescribing, doctors say taking it outside approved clinical settings amounts to an unregulated human experiment.
The articles also report safety concerns linked to the drug, including allegations that it has been associated with liver damage. The coverage frames the issue as a lack of oversight and limited publicly available safety data outside the trial environment, urging caution and compliance with regulated medical guidance. Overall, the reports highlight both the current regulatory status of retatrutide and the emergence of safety concerns cited by clinicians.
